MedTrace Logo

Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery

NCT01344226 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2018-10-22

Study results available
· View outcomes & findings →

Summary

Investigate the intraocular pressure(pressure inside the eye) of patients who are treated with Lotemax after undergoing cataract surgery.

Conditions

Interventions

DRUG

loteprednol 0.5% ophthalmic solution

Lotemax to be used QID starting day of cataract surgery and 21 days after for total of 22 days.

Sponsors & Collaborators

  • Toyos Clinic

    lead OTHER

Principal Investigators

  • Melissa Toyos, MD · Discover Vision Centers

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01344226 on ClinicalTrials.gov